British health authorities endorse the use of an injectable product to fight obesity

Managing overweight and obesity is one of the biggest challenges facing the UK health service, says Helen Knight, program director at the Center for Health Technology Assessment at the NICE or National Institute for Health and Care Excellence. Two-thirds of adults in the country are either obese or overweight.

Obesity is a lifelong condition that requires medical intervention. It has both a psychological and a physical impact, and also affects the quality of life. However, in recent years, the NICE Institute has been able to recommend, in addition to a healthy diet and regular exercise, the use of pharmaceutical treatments promoting weight loss.

In this context, the health authorities of the United Kingdom have just approved, and even recommended, the use of an injectable product which allows a weight loss of around 10%. Known as Semaglutide, this new treatment has shown excellent results in recent clinical trials. Its use is recommended for people with a body mass index (BMI) greater than 35kg/m2and to some extent, those with a BMI greater than 30kg/m2.

Product Features

Like Orlistat and Liraglutide, Semaglutide will now be among the drugs to be prescribed for weight loss, before turning to surgery. It is available at NHS level and will be priced at £73.25 ($100) a box.

The announcement of the new treatment follows a randomized double-blind STEP 1 clinical trial. During this trial, the use of Semaglutide over a period of 68 weeks allowed a weight loss of 12%, compared to a control group receiving placebo. The treatment is taken as a weekly injection and is used in conjunction with special diets or physical activity sessions.

According to the information, the drug acts on the GLP-1 receptors which are found in the pancreas and the brain. Semaglutide increases insulin secretion and slows gastric emptying, thus reducing the urge to eat.

Alarming statistics

Obesity is a growing problem in the UK. In England, more than one in four people (28%) suffer from obesity, and a further 36% are considered overweight. According to NICE, this situation creates a financial burden of around £6.1 billion ($8.62 billion) for the NHS and £27 billion ($36.6 billion) for society. in general. This problem is worsening as the population ages, with around three-quarters of the population between the ages of 45 and 74 estimated to be overweight or obese.

This new treatment will thus benefit people wishing to lose weight but who have difficulty achieving it. It will also ease pressure on the NHS from the overweight problem in the population.

SOURCE: IFLScience

Leave a Comment